Relevant bibliographies by topics / Antifibrotic Agents

Academic literature on the topic 'Antifibrotic Agents'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antifibrotic Agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antifibrotic Agents"

1

Albanis, E., and S. L. Friedman. "Antifibrotic Agents for Liver Disease." American Journal of Transplantation 6, no. 1 (January 2006): 12–19. http://dx.doi.org/10.1111/j.1600-6143.2005.01143.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

LaCamera, Peter P., Susan L. Limb, Tmirah Haselkorn, Elizabeth A. Morgenthien, John L. Stauffer, and Mark L. Wencel. "Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis." Chronic Respiratory Disease 16 (January 1, 2019): 147997311987967. http://dx.doi.org/10.1177/1479973119879678.

Full text
Abstract:
Pirfenidone and nintedanib are oral antifibrotic agents approved for the treatment of idiopathic pulmonary fibrosis (IPF). Real-world data on factors that influence IPF treatment decisions are limited. Physician characteristics associated with antifibrotic therapy initiation following an IPF diagnosis were examined in a sample of US pulmonologists. An online, self-administered survey was fielded to pulmonologists between April 10, 2017, and May 17, 2017. Pulmonologists were included if they spent >20% of their time in direct patient care and had ≥5 patients with IPF receiving antifibrotics. Participants answered questions regarding timing and reasons for considering the initiation of antifibrotic therapy after an IPF diagnosis. A total of 169 pulmonologists participated. The majority (81.7%) considered initiating antifibrotic therapy immediately after IPF diagnosis all or most of the time (immediate group), while 18.3% considered it only some of the time or not at all (delayed group). Pulmonologists in the immediate group were more likely to work in private practice (26.1%), have a greater mean percentage of patients receiving antifibrotic therapy (60.8%), and decide to initiate treatment themselves (31.2%) versus those in the delayed group (16.1%, 30.5%, and 16.1%, respectively). Most pulmonologists consider initiating antifibrotic treatment immediately after establishing an IPF diagnosis all or most of the time versus using a “watch-and-wait” approach. Distinguishing characteristics between pulmonologists in the immediate group versus the delayed group included practice setting, percentage of patients receiving antifibrotic therapy, and the decision-making dynamics between the patient and the pulmonologist.
APA, Harvard, Vancouver, ISO, and other styles
3

Skuta, Gregory L. "Antifibrotic Agents in Glaucoma Filtering Surgery." International Ophthalmology Clinics 33, no. 4 (1993): 165–82. http://dx.doi.org/10.1097/00004397-199303340-00014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Oishi, Keiji, Tsunahiko Hirano, Yoriyuki Murata, Kazuki Hamada, Sho Uehara, Ryo Suetake, Yoshikazu Yamaji, et al. "Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study." Therapeutic Advances in Respiratory Disease 13 (January 2019): 175346661987289. http://dx.doi.org/10.1177/1753466619872890.

Full text
Abstract:
Background: In patients with idiopathic pulmonary fibrosis (IPF), continuing treatment with antifibrotic agents is crucial to decrease the reduction of forced vital capacity and mortality rate. However, predictive factors for the discontinuation of antifibrotic agents are unknown. This study aims to investigate the clinical characteristics and predictive factors for the discontinuation of antifibrotic agents in patients with IPF. Methods: This was a double-center retrospective study that enrolled patients with IPF treated with pirfenidone or nintedanib between 2009 and 2017. We compared clinical parameters between the medication-continuing group and the discontinued group. The predictive factors were determined using Cox proportional hazards analyses. Results: A total of 66 subjects were included: 43 received pirfenidone and 23 received nintedanib. At 1 year, 23 of 66 patients had discontinued due to adverse events ( n = 12), disease progression ( n = 9), or death ( n = 2). The characteristics of the discontinuation group were poor performance status (PS) and delay from diagnosis to treatment. In the receiver operating characteristic (ROC) analysis associated with the discontinuation of antifibrotic agents, PS was the highest area under the ROC curve (AUC) value (cut-off value, 2; AUC, 0.83; specificity, 63%; sensitivity, 87%). This finding was consistent even when analyzing, except for examples of death and adjusting for the type of antifibrotic agent. The treatment persistence rate by PS was PS 0–1 = 90%, PS 2 = 65%, and PS 3 = 19%. Analysis of the relationship between PS and administration period of antifibrotic agents revealed that delays from diagnosis to treatment led to worsening of dyspnea, a decline in lung function, and deterioration of PS. Conclusions: PS may be informative for predicting discontinuation of medication. Our data reinforced the importance of early initiation of antifibrotic treatment, and we suggest PS should be used as a guide for starting antifibrotic agents in everyday practice. The reviews of this paper are available via the supplementary material section.
APA, Harvard, Vancouver, ISO, and other styles
5

Kawada, Norifumi. "Antifibrotic agents emerging from traditional herbal medicine." Arab Journal of Gastroenterology 10, no. 4 (April 2010): S21—S22. http://dx.doi.org/10.1016/j.ajg.2009.12.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Geismar, Lois S., Janet S. Kerr, Robert L. Trelstad, and David J. Riley. "Treatment of experimental silicosis with antifibrotic agents." Toxicology 53, no. 2-3 (December 1988): 331–44. http://dx.doi.org/10.1016/0300-483x(88)90225-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Grotendorst, Gary R. "Identification and development of novel antifibrotic agents." Expert Opinion on Investigational Drugs 6, no. 6 (June 1997): 777–81. http://dx.doi.org/10.1517/13543784.6.6.777.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jegal, Yangjin, Jong Sun Park, Song Yee Kim, Hongseok Yoo, Sung Hwan Jeong, Jin Woo Song, Jae Ha Lee, et al. "Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry." Tuberculosis and Respiratory Diseases 85, no. 2 (April 1, 2022): 185–94. http://dx.doi.org/10.4046/trd.2021.0123.

Full text
Abstract:
Background: The Korea Interstitial Lung Disease Study Group has made a new nationwide idiopathic pulmonary fibrosis (IPF) registry because the routine clinical practice has changed due to new guidelines and newly developed antifibrotic agents in the recent decade. The aim of this study was to describe recent clinical characteristics of Korean IPF patients.Methods: Both newly diagnosed and following IPF patients diagnosed after the previous registry in 2008 were enrolled. Survival analysis was only conducted for patients diagnosed with IPF after 2016 because antifibrotic agents started to be covered by medical insurance of Korea in October 2015.Results: A total of 2,139 patients were analyzed. Their mean age at diagnosis was 67.4±9.3 years. Of these patients, 76.1% were males, 71.0% were ever-smokers, 14.4% were asymptomatic at the time of diagnosis, and 56.9% were at gender-agephysiology stage I. Occupational toxic material exposure was reported in 534 patients. The mean forced vital capacity was 74.6% and the diffusing capacity for carbon monoxide was 63.6%. Treatment with pirfenidone was increased over time: 62.4% of IPF patients were treated with pirfenidone initially. And 79.2% of patients were treated with antifiboritics for more than three months during the course of the disease since 2016. Old age, acute exacerbation, treatment without antifibrotics, and exposure to wood and stone dust were associated with higher mortality.Conclusion: In the recent Korean IPF registry, the percentage of IPF patients treated with antifibrotics was increased compared to that in the previous IPF registry. Old age, acute exacerbation, treatment without antifibrotics, and exposure to wood and stone dust were associated with higher mortality.
APA, Harvard, Vancouver, ISO, and other styles
9

Schuppan, Detlef, Muhammad Ashfaq-Khan, Ai Ting Yang, and Yong Ook Kim. "Liver fibrosis: Direct antifibrotic agents and targeted therapies." Matrix Biology 68-69 (August 2018): 435–51. http://dx.doi.org/10.1016/j.matbio.2018.04.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pan, Xiaoqi, Xiao Ma, Yinxiao Jiang, Jianxia Wen, Lian Yang, Dayi Chen, Xiaoyu Cao, and Cheng Peng. "A Comprehensive Review of Natural Products against Liver Fibrosis: Flavonoids, Quinones, Lignans, Phenols, and Acids." Evidence-Based Complementary and Alternative Medicine 2020 (October 5, 2020): 1–19. http://dx.doi.org/10.1155/2020/7171498.

Full text
Abstract:
Liver fibrosis resulting from continuous long-term hepatic damage represents a heavy burden worldwide. Liver fibrosis is recognized as a complicated pathogenic mechanism with extracellular matrix (ECM) accumulation and hepatic stellate cell (HSC) activation. A series of drugs demonstrate significant antifibrotic activity in vitro and in vivo. No specific agents with ideally clinical efficacy for liver fibrosis treatment have been developed. In this review, we summarized the antifibrotic effects and molecular mechanisms of 29 kinds of common natural products. The mechanism of these compounds is correlated with anti-inflammatory, antiapoptotic, and antifibrotic activities. Moreover, parenchymal hepatic cell survival, HSC deactivation, and ECM degradation by interfering with multiple targets and signaling pathways are also involved in the antifibrotic effects of these compounds. However, there remain two bottlenecks for clinical breakthroughs. The low bioavailability of natural products should be improved, and the combined application of two or more compounds should be investigated for more prominent pharmacological effects. In summary, exploration on natural products against liver fibrosis is becoming increasingly extensive. Therefore, natural products are potential resources for the development of agents to treat liver fibrosis.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antifibrotic Agents"

1

Venalis, Paulius. "The performance of antifibrotic agents in preclinical models of systemic sclerosis." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2010. http://vddb.laba.lt/obj/LT-eLABa-0001:E.02~2010~D_20101001_150819-57019.

Full text
Abstract:
Systemic sclerosis (SSc) – is one of the most complicated and fatal systemic diseases, and the lack of effective therapy is very evident. The tyrosine kinase inhibitor imatinib mesylate (IM) was shown to inhibit TGF-β and PDGF signaling pathways and prevent the development of dermal fibrosis upon challenge with bleomycin in murine model of SSc. The aim of therapy is not only to stop disease progression, but even induce regression of preexisting fibrosis. On other hand, blocking TGF-β and PDGF signaling in angiogenesis might worsen the vascular manifestations of SSc. We found important to evaluate effectiveness of IM for the treatment of pre-established tissue fibrosis and to exclude that the anti-fibrotic effects of IM are complicated by inhibitory effects on endothelial cell functions. Aim of the study: assess the effect of IM on the process of fibrosis and endothelium in experimental models of systemic sclerosis and cell cultures. Objectives of the study: assess the effectiveness of IM on murine models of established fibrosis; evaluate if IM has an effect on basal functions of endothelial cells; assess effect of IM on the process of angiogenesis. We have shown that IM exerts potent antifibrotic effects in two different models of SSc. Imatinib was effective for prevention of fibrosis and for treatment of established dermal fibrosis. We’ve demonstrated that IM does not inhibit major functions of endothelial cells. Thus, IM might not augment further the preexisting vascular... [to full text]
Sisteminė sklerozė (SSc) – viena sunkiausių ir fatališkiausių autoimuninių sisteminių reumatinių ligų, o bazinių vaistų stygius, šiai ligai gydyti, itin didelis. Į onkologinę klinikinę praktiką įdiegtas tirozinkinazių inhibitorius – imatinibo mezilatas(IM). IM blokuoja TGF-β ir PDGF intraląstelinio signalo perdavimą ir taip sąlygoja fibrozės prevenciją SSc pelių modelyje. Mums buvo svarbu išsiaiškinti, ar imatinibas gali turėti įtakos ne tik prevencijai, bet ir susiformavusiai fibrozei. Be to TGF-β ir PDGF blokavimas angiogenezėje, galėtų riboti daug žadančio fibrozės inhibitoriaus IM naudojimą gydant SSc. Darbo tikslas: įvertinti imatinibo mezilato poveikį fibrozės procesui ir endoteliui sisteminės sklerozės eksperimentiniuose modeliuose ir ląstelių kultūrose. Darbo uždaviniai: įvertinti imatinibo efektyvumą neuždegiminiame SSc modelyje ir patikrinti imatinibo mezilato efektyvumą uždegiminiame suformuotos fibrozės modelyje; ištirti, ar terapinės imatinibo mezilato koncentracijos daro neigiamą poveikį gyvybinėms endotelio funkcijoms; įvertinti imatinibo mezilato poveikį angiogenezės etapams. Mūsų gauti duomenys rodo, kad: IM ne tik sustabdė bet ir paskatino jau egzistuojančios (bleomicino sukeltos) odos firbrozės regresiją; IM ryškiai sumažino poodžio ir odos storį, bei normalizavo miofibroblastų skaičių Tsk-1 pelėse; IM neturėjo poveikio endotelio ląstelių bazinėms funkcijoms; IM neturėjo neigiamo poveikio angiogenezės etapams.
APA, Harvard, Vancouver, ISO, and other styles
2

Brook, Nicholas Roger. "Nephrotoxicity of immunosuppressant drugs in salt-depletion and modification of effect by an antifibrotic agent." Thesis, University of Leicester, 2005. http://hdl.handle.net/2381/29914.

Full text
Abstract:
The calcineurin inhibitors, cyclosporine and tacrolimus, are pivotal immunosuppressants in renal transplantation, but produce a cascade of acute (functional) and chronic (fibrotic) injurious events that contribute to chronic allograft nephropathy (CAN). Using the rat salt depletion model of calcineurin inhibitor toxicity, this study aimed to examine the effects of clinically relevant combinations of cyclosporine, tacrolimus and sirolimus on renal functional, structural and molecular markers of injury. Further, the effect of pirfenidone when added to these drug combinations was examined. There were differences in the effects of cyclosporine and tacrolimus on functional and molecular variables, with tacrolimus displaying more favourable results. As sole therapy, sirolimus had no effect on renal function or messenger RNA expression. Deterioration in renal function and a deleterious effect on molecular markers of fibrosis were seen when cyclosporine and sirolimus were combined at high doses; at lower doses, favourable outcomes for these end-points were elicited. When sirolimus and tacrolimus were combined, renal function worsened and the beneficial molecular effects of tacrolimus were reversed. Pirfenidone's actions were non-dose dependent and beneficial effects for renal function and molecular markers were demonstrated. The effect of pirfenidone on renal function has not previously been described. There were no differences in urinary protein or interstitial fibrosis measurements across the groups. Without fibrosis, it is impossible to say whether pirfenidone acted in a truly antifibrotic manner. However, the molecular changes possibly represent interim markers of fibrosis, suggesting such an effect may have been developing.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Antifibrotic Agents"

1

Menke, A., R. Vogelmann, M. Bachem, and G. Adler. "Mechanisms of Fibrosis and Potential Antifibrotic Agents." In Pancreatic Disease, 132–39. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-60068-5_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lupher Jr., Mark L., and W. Scott Willett. "Serum amyloid P: A novel antifibrotic agent with therapeutic potential." In New Drugs and Targets for Asthma and COPD, 261–66. Basel: KARGER, 2010. http://dx.doi.org/10.1159/000320829.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Roth, Gerald J., Rudolf Binder, Florian Colbatzky, Claudia Dallinger, Rozsa Schlenker-Herceg, Frank Hilberg, Lutz Wollin, John Park, Alexander Pautsch, and Rolf Kaiser. "Discovery and Development of Nintedanib: A Novel Antiangiogenic and Antifibrotic Agent." In Successful Drug Discovery, 235–66. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2016. http://dx.doi.org/10.1002/9783527800315.ch11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Khaw, Peng Tee, and Jonathan Clarke. "Antifibrotic Agents in Glaucoma Surgery." In Ophthalmology, 1269–76. Elsevier, 2009. http://dx.doi.org/10.1016/b978-0-323-04332-8.00211-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pinós, José. "Antifibrotic Agents in Glaucoma Filtering Surgery." In Mastering the Techniques of Glaucoma Diagnosis and Management, 271. Jaypee Brothers Medical Publishers (P) Ltd., 2006. http://dx.doi.org/10.5005/jp/books/10502_30.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Athiya, Agarwal. "Chapter-175 Antifibrotic Agents in Glaucoma Filtering Surgery." In Textbook of Ophthalmology (Vol 1)-Amar Agarwal, 1534–40. Jaypee Brothers Medical Publishers (P) Ltd., 2002. http://dx.doi.org/10.5005/jp/books/10931_175.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Johr, Chadwick R. "Management of Hepatic and Pancreatic Involvement in Sjögren’s." In The Sjögren's Book, 363–66. Oxford University Press, 2022. http://dx.doi.org/10.1093/oso/9780197502112.003.0038.

Full text
Abstract:
Approximately 5% of Sjögren’s patients have involvement of the liver, pancreas, or biliary tree. These include autoimmune hepatitis, biliary cirrhosis, IgG4 syndrome, and scleroderma-related disorders. Diagnosed by laboratory testing (e.g., antimitochondrial or smooth muscle antibodies), imaging, or biopsy, the management includes anti-inflammatory or antifibrotic agents. Infections such as human immunodeficiency virus and hepatitis C are associated with dry eyes and dry mouth but are not a feature of autoimmune Sjögren’s and should be ruled out. Agents used to treat inflammation such as nonsteroidal anti-inflammatory drugs may elevate levels of liver enzymes. It is important to stage a patient’s hepatobiliary status in order to optimize treatment.
APA, Harvard, Vancouver, ISO, and other styles
8

Lee, Augustine S. "Management of Pulmonary Complications in Sjögren’s." In The Sjögren's Book, 276–85. Oxford University Press, 2022. http://dx.doi.org/10.1093/oso/9780197502112.003.0028.

Full text
Abstract:
Twenty percent to 30% of all Sjögren’s patients have some form of pulmonary symptoms. The most common ones involve dry trachea, pleuritic discomfort, cough, and shortness of breath (dyspnea). Over time, approximately 10% of patients develop interstitial changes that may progress to scarring, increased pulmonary pressure, and bronchiectasis. A variety of interstitial lung disease (ILD) have been identified in the context of Sjögren’s. Infrequently, some Sjögren’s patients present with vasculitis or thromboembolic or lymphoproliferative changes. Evaluating the lungs in Sjögren’s includes pulmonary function testing, high-resolution CT scanning, 2-D echocardiography, and sleep studies. Supportive measures such as humidification are useful. If there is evidence for systemic inflammation, disease-modifying agents such as cyclophosphamide, mycophenolate mofetil, antifibrotic agents, or azathioprine are prescribed.
APA, Harvard, Vancouver, ISO, and other styles
9

Springs, Clark L. "Corneal Complications." In Complications of Glaucoma Surgery. Oxford University Press, 2013. http://dx.doi.org/10.1093/oso/9780195382365.003.0042.

Full text
Abstract:
The desired effects of antifibrotic agents 5-fluorouracil (5-FU) and mitomycin-C (MMC) in glaucoma filtration surgery result from their ability to limit postoperative scarring by inhibiting vascular proliferation and fibroblastic transformation. However, these same mechanisms of action can have deleterious effects on surrounding normal tissues such as the cornea. Knowing how to use these agents is important in preventing antifibrotic-related complications. 5-FU is an inhibitor of DNA synthesis, specifically thymidylate synthetase, and blocks thymidine from being incorporated into DNA. In addition to affecting DNA synthesis, 5-FU also may be incorporated into RNA, interfering with RNA synthesis and therefore protein synthesis. Thus, it is more toxic to actively proliferating cells. In glaucoma filtration surgery, 5-FU is generally administered intraoperatively (50 mg/mL for 5 minutes). 5-FU can also be administered as a subconjunctival injection postoperatively with a dosage of 5.0–7.5 mg in 0.1–0.15 mL solution directly from the 50 mg/mL bottle. A series of injections may be given over several weeks and titrated based on clinical response. In addition to glaucoma filtration surgery, 5-FU has also been used for other ophthalmic applications such as pterygium surgery, lacrimal surgery, and during vitrectomy to prevent proliferative vitreoretinopathy. MMC is an alkylating agent that crosslinks DNA. It requires enzymatic activation via cytochrome p450 prior to exerting its inhibitory effects on DNA synthesis. MMC activity is independent of cell cycle and affects both actively replicating and nonreplicating cells. However, variations in enzymatic activity among individuals may contribute to the differences in efficacy, as well as toxicity of MMC. In glaucoma filtration surgery, MMC is typically administered as a single intraoperative application. It is applied after dissection of the conjunctival flap and prior to the formation of the scleral flap. Most surgeons use a dose of 0.1–0.5 mg/mL with an exposure time of 1–5 minutes depending upon the clinical indication. MMC use has also been well established for refractive surgery to prevent corneal haze after photorefractive keratectomy in patients at high risk of developing corneal haze, pterygium surgery, and corneal intraepithelial neoplasia. For more information on 5-FU and MMC in glaucoma surgery, see Chapter 3.
APA, Harvard, Vancouver, ISO, and other styles
10

Shrivastava, Anurag, and Kuldev Singh. "Noncorneal Complications." In Complications of Glaucoma Surgery. Oxford University Press, 2013. http://dx.doi.org/10.1093/oso/9780195382365.003.0043.

Full text
Abstract:
Most glaucoma specialists advocate the use of 5-fluorouracil (5-FU) and mitomycin-C (MMC) in various concentrations during the intraoperative and postoperative periods to help inhibit postoperative scarring, the primary cause of filtration surgery failure. Although the increased use of antifibrotic agents as adjunctive therapy to guarded filtration surgery has improved the likelihood of operative success, there are many additional complications associated with this class of medications. It is the nature of filtration surgery as it is performed today that successful drainage of aqueous comes with a price. Any adjunct that improves the intraocular pressure (IOP)-lowering success of surgery must be assessed in light of this increased risk. A leaking bleb is one of the most common complications seen after trabeculectomy and may occur at any point postoperatively. This complication has been reported with an incidence ranging between 17% and 42% according to one review. More recent estimates have been somewhat lower, at between 8% and 14.6%. The longer the postoperative follow-up, the greater the cumulative likelihood of bleb leakage. It is imperative that the bleb be checked periodically for leaks, primarily through examination and standard Seidel testing. Use of antifibrotic therapy is associated with increased formation of thin-walled cystic blebs, which are more likely to result in both short-term and long-term complications. The timing of a bleb leak will dictate management. Many early postoperative bleb leaks resolve without intervention but can significantly decrease the likelihood of trabeculectomy success. Early postoperative bleb leaks are often attributed to surgical technique and can generally be avoided by use of appropriate blunt instruments and careful attention to surgical detail. The simple use of nontoothed forceps when handling the conjunctiva can prevent small buttonhole conjunctival tears, which often result in early postoperative bleb leaks. However, even with careful manipulation, friable conjunctival tissue can be prone to small tears. While some have advocated the use of light cautery, or even tissue adhesives to close bleb leaks, the use of such techniques has diminished in the antifibrotic era. Intraoperative suturing of buttonholes is definitive.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antifibrotic Agents"

1

Sugino, K., Y. Nakamura, H. Shimizu, K. Matsumoto, M. Ando, K. Mori, E. Tsuboi, and S. Homma. "Treatment with Antifibrotic Agents in Pleuroparenchymal Fibroelastosis with Usual Interstitial Pneumonia." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a4097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nuñez-García, L., C. Valenzuela, T. Alonso, E. F. Vicente, J. Ancochea, and S. Castañeda. "FRI0461 Efficacy and safety of antifibrotic agents in idiopathic pulmonary fibrosis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.7208.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kogo, Mariko, Yukari Satsuma, Kaori Kusuda, Hiroaki Ikesue, Ryobu Mori, Daichi Fujimoto, Kazuma Nagata, et al. "Team support with pharmacists improved tolerability of antifibrotic agents for pulmonary fibrosis." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa4783.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Menárguez Blanc, R., V. García Jimenez, MC Rosado María, A. Arias Martínez, B. Zárate Tamames, Á. Pieras López, C. Álvarez Asteinza, et al. "5PSQ-103 Experience of antifibrotic agents in the treatment of idiopathic pulmonary fibrosis." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.420.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Arrieta, M., C. García, JM Caro, M. González, C. Rosas, and JM Ferrari. "5PSQ-105 Effectiveness and toxicity profile analysis of antifibrotic agents in idiopathic pulmonary fibrosis." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.538.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Yoon, J. K., J. I. Kim, and S. M. Choi. "Single-Cell Transcriptomic Analysis of Idiopathic Pulmonary Fibrosis Airway Organoids Treated with Antifibrotic Agents." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4356.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Strens, Danielle, Benjamin Bondue, Caroline Dahlqvist, Hans Slabbynck, Julien Guiot, Guy Joos, Natacha Gusbin, Gil Wirtz, Antoine Froidure, and Wim Wuyts. "Long-term tolerability of real-life use of antifibrotic agents (AFA) in Idiopathic Pulmonary Fibrosis (IPF)." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa465.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, M. Y., C. M. Tseng, and C. W. Tao. "Treating Scleroderma-Related Interstitial Lung Disease with a New Antifibrotic Agent." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1525.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antifibrotic Agents' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography